These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 24962069)
1. Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome. Iulita MF; Cuello AC Trends Pharmacol Sci; 2014 Jul; 35(7):338-48. PubMed ID: 24962069 [TBL] [Abstract][Full Text] [Related]
2. The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease. Iulita MF; Cuello AC Curr Alzheimer Res; 2016; 13(1):53-67. PubMed ID: 26391047 [TBL] [Abstract][Full Text] [Related]
3. Nerve growth factor metabolic dysfunction in Down's syndrome brains. Iulita MF; Do Carmo S; Ower AK; Fortress AM; Flores Aguilar L; Hanna M; Wisniewski T; Granholm AC; Buhusi M; Busciglio J; Cuello AC Brain; 2014 Mar; 137(Pt 3):860-72. PubMed ID: 24519975 [TBL] [Abstract][Full Text] [Related]
4. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Salehi A; Delcroix JD; Belichenko PV; Zhan K; Wu C; Valletta JS; Takimoto-Kimura R; Kleschevnikov AM; Sambamurti K; Chung PP; Xia W; Villar A; Campbell WA; Kulnane LS; Nixon RA; Lamb BT; Epstein CJ; Stokin GB; Goldstein LS; Mobley WC Neuron; 2006 Jul; 51(1):29-42. PubMed ID: 16815330 [TBL] [Abstract][Full Text] [Related]
5. The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy. Do Carmo S; Kannel B; Cuello AC Cells; 2021 Dec; 11(1):. PubMed ID: 35011577 [TBL] [Abstract][Full Text] [Related]
6. A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome. Iulita MF; Caraci F; Cuello AC CNS Neurol Disord Drug Targets; 2016; 15(4):434-47. PubMed ID: 26996175 [TBL] [Abstract][Full Text] [Related]
7. Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. Pentz R; Iulita MF; Ducatenzeiler A; Videla L; Benejam B; Carmona‐Iragui M; Blesa R; Lleó A; Fortea J; Cuello AC Alzheimers Dement; 2021 Apr; 17(4):605-617. PubMed ID: 33226181 [TBL] [Abstract][Full Text] [Related]
8. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Fahnestock M; Michalski B; Xu B; Coughlin MD Mol Cell Neurosci; 2001 Aug; 18(2):210-20. PubMed ID: 11520181 [TBL] [Abstract][Full Text] [Related]
9. The cholinergic system in aging and neuronal degeneration. Schliebs R; Arendt T Behav Brain Res; 2011 Aug; 221(2):555-63. PubMed ID: 21145918 [TBL] [Abstract][Full Text] [Related]
10. APP, NGF & the 'Sunday-driver' in a Trolley on the Road. Heese K; Inoue N; Nagai Y; Sawada T Restor Neurol Neurosci; 2004; 22(2):131-6. PubMed ID: 15272147 [TBL] [Abstract][Full Text] [Related]
11. The failure in NGF maturation and its increased degradation as the probable cause for the vulnerability of cholinergic neurons in Alzheimer's disease. Cuello AC; Bruno MA Neurochem Res; 2007 Jun; 32(6):1041-5. PubMed ID: 17404842 [TBL] [Abstract][Full Text] [Related]
12. Nerve Growth Factor Compromise in Down Syndrome. Do Carmo S; Kannel B; Cuello AC Front Aging Neurosci; 2021; 13():719507. PubMed ID: 34434101 [TBL] [Abstract][Full Text] [Related]
13. Amyloid beta-induced nerve growth factor dysmetabolism in Alzheimer disease. Bruno MA; Leon WC; Fragoso G; Mushynski WE; Almazan G; Cuello AC J Neuropathol Exp Neurol; 2009 Aug; 68(8):857-69. PubMed ID: 19606067 [TBL] [Abstract][Full Text] [Related]
14. The hAPP-YAC transgenic model has elevated UPS activity in the frontal cortex similar to Alzheimer's disease and Down's syndrome. Seo H; Isacson O J Neurochem; 2010 Sep; 114(6):1819-26. PubMed ID: 20698932 [TBL] [Abstract][Full Text] [Related]
15. ProNGF, sortilin, and age-related neurodegeneration. Al-Shawi R; Hafner A; Chun S; Raza S; Crutcher K; Thrasivoulou C; Simons P; Cowen T Ann N Y Acad Sci; 2007 Nov; 1119():208-15. PubMed ID: 18056969 [TBL] [Abstract][Full Text] [Related]
16. A new role for matrix metalloproteinase-3 in the NGF metabolic pathway: Proteolysis of mature NGF and sex-specific differences in the continuum of Alzheimer's pathology. Pentz R; Iulita MF; Mikutra-Cencora M; Ducatenzeiler A; Bennett DA; Cuello AC Neurobiol Dis; 2021 Jan; 148():105150. PubMed ID: 33130223 [TBL] [Abstract][Full Text] [Related]
17. Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. Xu W; Weissmiller AM; White JA; Fang F; Wang X; Wu Y; Pearn ML; Zhao X; Sawa M; Chen S; Gunawardena S; Ding J; Mobley WC; Wu C J Clin Invest; 2016 May; 126(5):1815-33. PubMed ID: 27064279 [TBL] [Abstract][Full Text] [Related]
18. The NGF Metabolic Pathway: New Opportunities for Biomarker Research and Drug Target Discovery : NGF Pathway Biomarkers and Drug Targets. Pentz R; Iulita MF Adv Exp Med Biol; 2021; 1331():31-48. PubMed ID: 34453291 [TBL] [Abstract][Full Text] [Related]
19. NGF and the Amyloid Precursor Protein in Alzheimer's Disease: From Molecular Players to Neuronal Circuits. Triaca V; Ruberti F; Canu N Adv Exp Med Biol; 2021; 1331():145-165. PubMed ID: 34453297 [TBL] [Abstract][Full Text] [Related]
20. The cholinergic system, nerve growth factor and the cytoskeleton. Niewiadomska G; Mietelska-Porowska A; Mazurkiewicz M Behav Brain Res; 2011 Aug; 221(2):515-26. PubMed ID: 20170684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]